Astellas Forecasts Earnings Decline; Says Urology Franchise Will Drive Global Growth
Astellas recently reported declining sales, operating income and profits for fiscal year 2008 due to the appreciation of the yen and the revision of Japan's drug pricing policy. The decline in sales and earnings was the first to be posted since the 2005 merger between Fujisawa and Yamanouchi Pharmaceutical
More from Archive
More from Scrip
The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.